vs
Side-by-side financial comparison of CF Industries (CF) and Moderna (MRNA). Click either name above to swap in a different company.
CF Industries is the larger business by last-quarter revenue ($1.9B vs $1.0B, roughly 1.8× Moderna). CF Industries runs the higher net margin — 26.4% vs -19.7%, a 46.1% gap on every dollar of revenue. On growth, CF Industries posted the faster year-over-year revenue change (22.8% vs -45.4%). CF Industries produced more free cash flow last quarter ($313.0M vs $-880.0M). Over the past eight quarters, CF Industries's revenue compounded faster (12.8% CAGR vs -45.0%).
CF Industries Holdings, Inc. is an American manufacturer and distributor of agricultural fertilizers, including ammonia, urea, and ammonium nitrate products. The company is based in Northbrook, Illinois, a suburb of Chicago, and was founded in 1946 as the Central Farmers Fertilizer Company. For its first 56 years, it was a federation of regional agricultural supply cooperatives. CF then demutualized, and became a publicly traded company.
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
CF vs MRNA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $1.0B |
| Net Profit | $495.0M | $-200.0M |
| Gross Margin | 40.9% | 79.6% |
| Operating Margin | 33.0% | -25.6% |
| Net Margin | 26.4% | -19.7% |
| Revenue YoY | 22.8% | -45.4% |
| Net Profit YoY | 26.3% | -1638.5% |
| EPS (diluted) | $2.56 | $-0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.7B | $1.0B | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.5B | $966.0M | ||
| Q3 24 | $1.4B | $1.9B | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.5B | — |
| Q4 25 | $495.0M | — | ||
| Q3 25 | $460.0M | $-200.0M | ||
| Q2 25 | $492.0M | — | ||
| Q1 25 | $351.0M | — | ||
| Q4 24 | $392.0M | $-1.1B | ||
| Q3 24 | $341.0M | $13.0M | ||
| Q2 24 | $506.0M | — | ||
| Q1 24 | $238.0M | — |
| Q4 25 | 40.9% | — | ||
| Q3 25 | 38.1% | 79.6% | ||
| Q2 25 | 39.9% | — | ||
| Q1 25 | 34.4% | — | ||
| Q4 24 | 34.4% | 23.5% | ||
| Q3 24 | 32.4% | 72.4% | ||
| Q2 24 | 43.2% | — | ||
| Q1 24 | 27.8% | — |
| Q4 25 | 33.0% | — | ||
| Q3 25 | 35.0% | -25.6% | ||
| Q2 25 | 34.3% | — | ||
| Q1 25 | 27.4% | — | ||
| Q4 24 | 28.9% | -129.0% | ||
| Q3 24 | 26.6% | -3.8% | ||
| Q2 24 | 40.6% | — | ||
| Q1 24 | 20.6% | — |
| Q4 25 | 26.4% | — | ||
| Q3 25 | 27.7% | -19.7% | ||
| Q2 25 | 26.0% | — | ||
| Q1 25 | 21.1% | — | ||
| Q4 24 | 25.7% | -115.9% | ||
| Q3 24 | 24.9% | 0.7% | ||
| Q2 24 | 32.2% | — | ||
| Q1 24 | 16.2% | — |
| Q4 25 | $2.56 | — | ||
| Q3 25 | $2.19 | $-0.51 | ||
| Q2 25 | $2.37 | — | ||
| Q1 25 | $1.85 | — | ||
| Q4 24 | $1.86 | $-2.91 | ||
| Q3 24 | $1.55 | $0.03 | ||
| Q2 24 | $2.30 | — | ||
| Q1 24 | $1.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.1B |
| Total DebtLower is stronger | $3.2B | — |
| Stockholders' EquityBook value | $4.8B | $9.3B |
| Total Assets | $14.1B | $12.1B |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.9B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.0B | — | ||
| Q2 25 | $3.0B | — | ||
| Q1 25 | $3.0B | — | ||
| Q4 24 | $3.0B | — | ||
| Q3 24 | $3.0B | — | ||
| Q2 24 | $3.0B | — | ||
| Q1 24 | $3.0B | — |
| Q4 25 | $4.8B | — | ||
| Q3 25 | $4.8B | $9.3B | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $4.8B | — | ||
| Q4 24 | $5.0B | $10.9B | ||
| Q3 24 | $5.2B | $11.9B | ||
| Q2 24 | $5.5B | — | ||
| Q1 24 | $5.4B | — |
| Q4 25 | $14.1B | — | ||
| Q3 25 | $14.2B | $12.1B | ||
| Q2 25 | $13.8B | — | ||
| Q1 25 | $13.3B | — | ||
| Q4 24 | $13.5B | $14.1B | ||
| Q3 24 | $13.8B | $15.8B | ||
| Q2 24 | $13.8B | — | ||
| Q1 24 | $13.9B | — |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 0.60× | — | ||
| Q1 25 | 0.62× | — | ||
| Q4 24 | 0.60× | — | ||
| Q3 24 | 0.57× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | 0.55× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $539.0M | $-847.0M |
| Free Cash FlowOCF − Capex | $313.0M | $-880.0M |
| FCF MarginFCF / Revenue | 16.7% | -86.6% |
| Capex IntensityCapex / Revenue | 12.1% | 3.2% |
| Cash ConversionOCF / Net Profit | 1.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.8B | $-1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $539.0M | — | ||
| Q3 25 | $1.1B | $-847.0M | ||
| Q2 25 | $563.0M | — | ||
| Q1 25 | $586.0M | — | ||
| Q4 24 | $420.0M | $825.0M | ||
| Q3 24 | $931.0M | $-1.6B | ||
| Q2 24 | $475.0M | — | ||
| Q1 24 | $445.0M | — |
| Q4 25 | $313.0M | — | ||
| Q3 25 | $717.0M | $-880.0M | ||
| Q2 25 | $318.0M | — | ||
| Q1 25 | $454.0M | — | ||
| Q4 24 | $223.0M | $303.0M | ||
| Q3 24 | $792.0M | $-1.7B | ||
| Q2 24 | $391.0M | — | ||
| Q1 24 | $347.0M | — |
| Q4 25 | 16.7% | — | ||
| Q3 25 | 43.2% | -86.6% | ||
| Q2 25 | 16.8% | — | ||
| Q1 25 | 27.3% | — | ||
| Q4 24 | 14.6% | 31.4% | ||
| Q3 24 | 57.8% | -92.2% | ||
| Q2 24 | 24.9% | — | ||
| Q1 24 | 23.6% | — |
| Q4 25 | 12.1% | — | ||
| Q3 25 | 20.9% | 3.2% | ||
| Q2 25 | 13.0% | — | ||
| Q1 25 | 7.9% | — | ||
| Q4 24 | 12.9% | 54.0% | ||
| Q3 24 | 10.1% | 8.1% | ||
| Q2 24 | 5.3% | — | ||
| Q1 24 | 6.7% | — |
| Q4 25 | 1.09× | — | ||
| Q3 25 | 2.31× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.67× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 2.73× | -120.46× | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 1.87× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CF
| Ammonia | $591.0M | 32% |
| UAN | $493.0M | 26% |
| Urea | $372.0M | 20% |
| Other | $244.0M | 13% |
| Other Products | $147.0M | 8% |
| Ammonium Nitrate Segment | $25.0M | 1% |
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
